• Neuroligin 1, D2-MSNs, and Repetitive Behavior

  2026-08-24

  This study identifies striatal dopamine receptor D2-expressing medium spiny neurons as a cell-type-specific circuit substrate for autistic-like repetitive behavior after Neuroligin 1 loss. By integrating behavioral analysis, neuronal activity manipulation, single-nucleus RNA sequencing, and protein validation, it links D2-MSN hyperactivation to PKC overactivation and separates the activity patterns associated with self-grooming and digging.

• BMS-345541 hydrochloride: IKK Workflows

  2026-08-24

  Use BMS-345541 hydrochloride as a selective NF-κB pathway probe for separating inflammatory transcription from RIPK1-linked cell-death decisions. This guide translates its allosteric IKK activity into practical workflows for inflammation research, T-ALL studies, and mechanism-driven cancer biology research.

• PPP1R3G/PP1γ Control of RIPK1 Cell Death

  2026-08-23

  The reference study identifies PPP1R3G as a regulatory adaptor that recruits PP1γ to dephosphorylate and activate RIPK1, thereby promoting RIPK1-dependent apoptosis and type I necroptosis. Its combination of sensitized genome-wide screening, genetic rescue, phosphosite manipulation, and mouse validation provides a mechanistic framework for studying how inflammatory signaling is converted into cell death.

• Bay 11-7085: From NF-κB Blockade to Assay Design

  2026-08-22

  Bay 11-7085 is an NF-κB activation inhibitor that can do more than suppress inflammatory readouts. This article explains how to use it as a mechanistic probe across ER-stress inflammation, apoptosis, endometriosis, and neuroinflammation while separating pathway effects from nonspecific cytotoxicity.

• JSH-23 for Reliable NF-κB Assays

  2026-08-22

  This scenario-based guide explains how JSH-23 (SKU B1645) can improve the interpretation and reproducibility of cell viability, proliferation, and inflammatory-response assays. It covers mechanism, controls, solvent preparation, concentration selection, data interpretation, and practical supplier evaluation.

• Anlotinib hydrochloride: Practical Angiogenesis Assays

  2026-08-21

  Build more informative angiogenesis experiments by pairing endothelial migration and tube formation readouts with receptor-level validation. This workflow shows how Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, can distinguish VEGFR2-, PDGFRβ-, and FGFR1-driven responses while highlighting controls that reduce assay noise.

• AZD1480: Mapping JAK2/STAT3 Escape

  2026-08-20

  AZD1480 is a potent JAK2 inhibitor for investigating tumor-intrinsic STAT3 activation and adaptive survival signaling. This guide translates recent IDO1 research into compartment-aware assays, model selection strategies, and practical workflows for cancer biology.

• (S)-(+)-Dimethindene maleate: M2 Antagonist

  2026-08-20

  This practical guide explains how (S)-(+)-Dimethindene maleate (SKU B6734) can support M2 muscarinic receptor antagonist workflows while accounting for its additional histamine H1 activity. It is intended for controlled pharmacological research, not diagnostic, therapeutic, or broad non-selective muscarinic applications.

• Resiquimod in Safer Tumor Ablation

  2026-08-19

  Resiquimod (R-848) is more than a TLR7/8 agonist: when integrated with thermal-protective biomaterials, it becomes a controllable variable in post-ablation immune engineering. This article examines the mechanism, evidence, workflow implications, and translational limits of that strategy.

• CTCF, Centromere Function, and Mitotic Fidelity

  2026-08-19

  Walsh and colleagues use rapid, inducible CTCF degradation to show that CTCF maintains centromere mechanics, metaphase alignment, and accurate mitosis rather than simply recruiting CENP-E. The findings position CTCF as a centromere maintenance factor and provide a framework for distinguishing architectural defects from motor-protein inhibition in mitosis-focused cancer research.

• Romidepsin (FK228): Designing Mechanism-Linked Assays

  2026-08-18

  Romidepsin (FK228) is a selective class I HDAC inhibitor for linking chromatin remodeling to cell-cycle and apoptotic phenotypes. This guide translates proteomic and thermal-stability concepts into better assay design while clearly separating evidence for Romidepsin from findings generated with Platycodin D.

• AR and ARv7 Targeting in Triple-Negative Breast Cancer

  2026-08-18

  This 2025 study links androgen receptor (AR) and AR splice variant 7 (ARv7) expression with unfavorable outcomes and distant metastasis in triple-negative breast cancer (TNBC). By combining patient tissue analysis, TCGA-BRCA bioinformatics, and MDA-MB-231 experiments, it shows that enzalutamide and EPI-001 modulate metastasis and epithelial-to-mesenchymal transition markers, supporting ARv7 as a clinically relevant biomarker and N-terminal targeting as a mechanistic research strategy.

• Simvastatin and Membrane Bilayer Modulation

  2026-08-17

  The 2021 study by Teo and Tieleman used all-atom molecular dynamics simulations to distinguish how the lactone and active dihydroxyheptanoate forms of Simvastatin partition into and reshape phospholipid bilayers. Its results connect simvastatin chemical state and membrane composition with changes in localization, hydrogen bonding, membrane order, and fluidity, offering a mechanistic framework for interpreting both therapeutic and pleiotropic effects.

• Bromodomain Inhibitor (+)-JQ1: Applied Workflows

  2026-08-17

  Build reproducible BET-signaling experiments with (+)-JQ1 across transcriptional regulation, apoptosis, ferroptosis sensitivity, inflammation, and BRDT-focused reproductive biology. This guide connects practical dosing and assay design to a 2025 BRD4–TXNIP–UFMylation mechanism while emphasizing solvent control, timing, and orthogonal validation.

• Lipo3K Transfection Reagent for Ferroptosis

  2026-08-16

  Lipo3K Transfection Reagent enables a mechanism-focused workflow for studying OTUD3, SLC7A11, and sunitinib resistance in clear cell renal cell carcinoma. This guide connects low-toxicity nucleic acid delivery with rigorous gene expression studies and RNA interference research, while separating product capabilities from literature-derived findings.

8106 records 1/541 page Next 12345 下5页 Last page